Douglas A. Treco - 06 Aug 2025 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role: Director
Signature: /s/ Elizabeth Ryland Waldinger, attorney-in-fact
Issuer symbol: CRSP
Transactions as of: 06 Aug 2025
Net transactions value: +$1,140,600
Form type: 4
Filing time: 08 Aug 2025, 16:06:28 UTC
Previous filing: 03 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Treco Douglas A	Director	C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	08 Aug 2025	0001688192

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRSP	Common Shares	Purchase	$1,140,600	+20,000	+1000%	$57.03	22,000	06 Aug 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Open market purchase of shares in accordance with Issuer's trading policies.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.92 to $57.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Content

Open market purchase of shares in accordance with Issuer's trading policies.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.92 to $57.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.